The use of adenoviral vectors in gene therapy and vaccine approaches
Abstract Adenovirus was first identified in the 1950s and since then this pathogenic group of viruses has been explored and transformed into a genetic transfer vehicle. Modification or deletion of few genes are necessary to transform it into a conditionally or non-replicative vector, creating a versatile tool capable of transducing different tissues and inducing high levels of transgene expression. In the early years of vector development, the application in monogenic diseases faced several hurdles, including short-term gene expression and even a fatality. On the other hand, an adenoviral delivery strategy for treatment of cancer was the first approved gene therapy product. There is an increasing interest in expressing transgenes with therapeutic potential targeting the cancer hallmarks, inhibiting metastasis, inducing cancer cell death or modulating the immune system to attack the tumor cells. Replicative adenovirus as vaccines may be even older and date to a few years of its discovery, application of non-replicative adenovirus for vaccination against different microorganisms has been investigated, but only recently, it demonstrated its full potential being one of the leading vaccination tools for COVID-19. This is not a new vector nor a new technology, but the result of decades of careful and intense work in this field.
Main Authors: | , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Brasileira de Genética
2022
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572022000400108 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S1415-47572022000400108 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S1415-475720220004001082022-10-04The use of adenoviral vectors in gene therapy and vaccine approachesAraújo,Natália MenesesRubio,Ileana Gabriela SanchezToneto,Nicholas Pietro AgulhaMorale,Mirian GallioteTamura,Rodrigo Esaki Adenovirus gene therapy monogenic diseases cancer vaccines Abstract Adenovirus was first identified in the 1950s and since then this pathogenic group of viruses has been explored and transformed into a genetic transfer vehicle. Modification or deletion of few genes are necessary to transform it into a conditionally or non-replicative vector, creating a versatile tool capable of transducing different tissues and inducing high levels of transgene expression. In the early years of vector development, the application in monogenic diseases faced several hurdles, including short-term gene expression and even a fatality. On the other hand, an adenoviral delivery strategy for treatment of cancer was the first approved gene therapy product. There is an increasing interest in expressing transgenes with therapeutic potential targeting the cancer hallmarks, inhibiting metastasis, inducing cancer cell death or modulating the immune system to attack the tumor cells. Replicative adenovirus as vaccines may be even older and date to a few years of its discovery, application of non-replicative adenovirus for vaccination against different microorganisms has been investigated, but only recently, it demonstrated its full potential being one of the leading vaccination tools for COVID-19. This is not a new vector nor a new technology, but the result of decades of careful and intense work in this field.info:eu-repo/semantics/openAccessSociedade Brasileira de GenéticaGenetics and Molecular Biology v.45 n.3 suppl.1 20222022-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572022000400108en10.1590/1678-4685-gmb-2022-0079 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Araújo,Natália Meneses Rubio,Ileana Gabriela Sanchez Toneto,Nicholas Pietro Agulha Morale,Mirian Galliote Tamura,Rodrigo Esaki |
spellingShingle |
Araújo,Natália Meneses Rubio,Ileana Gabriela Sanchez Toneto,Nicholas Pietro Agulha Morale,Mirian Galliote Tamura,Rodrigo Esaki The use of adenoviral vectors in gene therapy and vaccine approaches |
author_facet |
Araújo,Natália Meneses Rubio,Ileana Gabriela Sanchez Toneto,Nicholas Pietro Agulha Morale,Mirian Galliote Tamura,Rodrigo Esaki |
author_sort |
Araújo,Natália Meneses |
title |
The use of adenoviral vectors in gene therapy and vaccine approaches |
title_short |
The use of adenoviral vectors in gene therapy and vaccine approaches |
title_full |
The use of adenoviral vectors in gene therapy and vaccine approaches |
title_fullStr |
The use of adenoviral vectors in gene therapy and vaccine approaches |
title_full_unstemmed |
The use of adenoviral vectors in gene therapy and vaccine approaches |
title_sort |
use of adenoviral vectors in gene therapy and vaccine approaches |
description |
Abstract Adenovirus was first identified in the 1950s and since then this pathogenic group of viruses has been explored and transformed into a genetic transfer vehicle. Modification or deletion of few genes are necessary to transform it into a conditionally or non-replicative vector, creating a versatile tool capable of transducing different tissues and inducing high levels of transgene expression. In the early years of vector development, the application in monogenic diseases faced several hurdles, including short-term gene expression and even a fatality. On the other hand, an adenoviral delivery strategy for treatment of cancer was the first approved gene therapy product. There is an increasing interest in expressing transgenes with therapeutic potential targeting the cancer hallmarks, inhibiting metastasis, inducing cancer cell death or modulating the immune system to attack the tumor cells. Replicative adenovirus as vaccines may be even older and date to a few years of its discovery, application of non-replicative adenovirus for vaccination against different microorganisms has been investigated, but only recently, it demonstrated its full potential being one of the leading vaccination tools for COVID-19. This is not a new vector nor a new technology, but the result of decades of careful and intense work in this field. |
publisher |
Sociedade Brasileira de Genética |
publishDate |
2022 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572022000400108 |
work_keys_str_mv |
AT araujonataliameneses theuseofadenoviralvectorsingenetherapyandvaccineapproaches AT rubioileanagabrielasanchez theuseofadenoviralvectorsingenetherapyandvaccineapproaches AT tonetonicholaspietroagulha theuseofadenoviralvectorsingenetherapyandvaccineapproaches AT moralemiriangalliote theuseofadenoviralvectorsingenetherapyandvaccineapproaches AT tamurarodrigoesaki theuseofadenoviralvectorsingenetherapyandvaccineapproaches AT araujonataliameneses useofadenoviralvectorsingenetherapyandvaccineapproaches AT rubioileanagabrielasanchez useofadenoviralvectorsingenetherapyandvaccineapproaches AT tonetonicholaspietroagulha useofadenoviralvectorsingenetherapyandvaccineapproaches AT moralemiriangalliote useofadenoviralvectorsingenetherapyandvaccineapproaches AT tamurarodrigoesaki useofadenoviralvectorsingenetherapyandvaccineapproaches |
_version_ |
1756419344400646144 |